Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
NCT05119179 on ClinicalTrials.gov · last registry update 2026-03-17
An unusually large phase 4: 300 participants, more than double the 75 typical for the stage. Due to report 31 October 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Mean change in beta cell responsivity. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 22 November 2021 — 4 years so far. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- Other
- Enrollment
- 300
- Started
- 2021-11-22
- Primary completion
- 2026-10-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean change in beta cell responsivity
Conditions studied
PreDiabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.